These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 8932560)
1. Evaluation of dexfenfluramine in a weight loss program for obese infertile women. Galletly C; Clark A; Tomlinson L Int J Eat Disord; 1996 Mar; 19(2):209-12. PubMed ID: 8932560 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225 [TBL] [Abstract][Full Text] [Related]
3. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K; J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224 [TBL] [Abstract][Full Text] [Related]
4. [Effect of dexfenfluramine on eating behavior and body weight of obese patients: results of a field study of Isomeride in Austrian general practice]. Geyer G; Haidinger G; Francesconi M; Langmayr N; Prager R; Schoberberger R; Toplak H; von Kalckreuth G; Kunze M Acta Med Austriaca; 1995; 22(5):95-101; 104-9. PubMed ID: 8651045 [TBL] [Abstract][Full Text] [Related]
5. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005 [TBL] [Abstract][Full Text] [Related]
6. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study. Mathus-Vliegen EM; Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193 [TBL] [Abstract][Full Text] [Related]
7. Possible thermogenesis with dexfenfluramine. Roongpisuthipong C; Panpakdee O; Boontawee A; Kulapongse S; Tanphaichitr V J Med Assoc Thai; 1999 Feb; 82(2):150-9. PubMed ID: 10087722 [TBL] [Abstract][Full Text] [Related]
8. [A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group]. Enzi G Ter Arkh; 1997; 69(5):71-5. PubMed ID: 9235665 [TBL] [Abstract][Full Text] [Related]
9. A close look at fenfluramine and dexfenfluramine. Vivero LE; Anderson PO; Clark RF J Emerg Med; 1998; 16(2):197-205. PubMed ID: 9543401 [TBL] [Abstract][Full Text] [Related]
10. Prolonged weight loss with dexfenfluramine treatment in obese patients. Finer N; Craddock D; Lavielle R; Keen H Diabete Metab; 1987; 13(6):598-602. PubMed ID: 3329122 [TBL] [Abstract][Full Text] [Related]
11. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099 [TBL] [Abstract][Full Text] [Related]
12. Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors. Chow CC; Ko GT; Tsang LW; Yeung VT; Chan JC; Cockram CS Diabetes Care; 1997 Jul; 20(7):1122-7. PubMed ID: 9203448 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dexfenfluramine in obese patients: a multicenter study. Enzi G; Crepaldi G; Inelmen EM; Bruni R; Baggio B Clin Neuropharmacol; 1988; 11 Suppl 1():S173-8. PubMed ID: 3052815 [TBL] [Abstract][Full Text] [Related]
14. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up. O'Connor HT; Richman RM; Steinbeck KS; Caterson ID Int J Obes Relat Metab Disord; 1995 Mar; 19(3):181-9. PubMed ID: 7780494 [TBL] [Abstract][Full Text] [Related]
15. Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine. Hainer V; Kunesova M; Bellisle F; Hill M; Braunerova R; Wagenknecht M Int J Obes (Lond); 2005 Feb; 29(2):208-16. PubMed ID: 15583700 [TBL] [Abstract][Full Text] [Related]
16. The relationship between health-related quality of life and weight loss. Kolotkin RL; Crosby RD; Williams GR; Hartley GG; Nicol S Obes Res; 2001 Sep; 9(9):564-71. PubMed ID: 11557837 [TBL] [Abstract][Full Text] [Related]
17. The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks. Drent ML; Zelissen PM; Koppeschaar HP; Nieuwenhuyzen Kruseman AC; Lutterman JA; van der Veen EA Int J Obes Relat Metab Disord; 1995 May; 19(5):299-304. PubMed ID: 7647820 [TBL] [Abstract][Full Text] [Related]
18. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. Weissman NJ; Tighe JF; Gottdiener JS; Gwynne JT N Engl J Med; 1998 Sep; 339(11):725-32. PubMed ID: 9731088 [TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of dexfenfluramine treatment in obese adolescents]. Małecka-Tendera E; Koehler B; Muchacka M; Wazowski R; Trzciakowska A Pediatr Pol; 1996 May; 71(5):431-6. PubMed ID: 8710426 [TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Appolinario JC; Bacaltchuk J; Sichieri R; Claudino AM; Godoy-Matos A; Morgan C; Zanella MT; Coutinho W Arch Gen Psychiatry; 2003 Nov; 60(11):1109-16. PubMed ID: 14609886 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]